• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.46% Nasdaq Up0.11%

    Opko Health, Inc. (OPK)

    -NYSE
    9.53 Down 0.08(0.78%) 12:19PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Opko Health, Inc.
    4400 Biscayne Boulevard
    Miami, FL 33137
    United States - Map
    Phone: 305-575-4100
    Website: http://www.opko.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Medical Appliances & Equipment
    Full Time Employees:625

    Business Summary 

    Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company develops a range of solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals, and vaccines. Its product pipeline includes various pharmaceutical compounds and technologies in research and development for a range of indications and conditions. The company’s lead products comprise RayaldyTM, a vitamin D prohormone, which in phase III clinical development stage to treat secondary hyperparathyroidism in patients with stage III or IV chronic kidney disease and vitamin D insufficiency; and Alpharen, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. It also manufactures, sells, and licenses specialty active pharmaceutical ingredients for pharmaceutical companies. In addition, the company is involved in the discovery of new drugs for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and developing a protein-based influenza vaccine that would offer protection against influenza, as well as has various therapeutic agents for respiratory disorders in clinical development, including products for asthma, chronic obstructive pulmonary disease, and chronic cough. Further, it develops rolapitant, a potent and selective competitive antagonist that has completed phase II clinical testing for prevention of chemotherapy induced nausea and vomiting. It also operates OPKO Lab, a full-service medical laboratory specializing in urologic pathology. The company operates in the United States, Chile, Spain, Israel, Mexico, and Ireland. OPKO Health, Inc. is based in Miami, Florida.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Opko Health, Inc.

    Corporate Governance 
    Opko Health, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 2; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Phillip Frost M.D., 77
    Chairman and Chief Exec. Officer
    N/AN/A
    Dr. Jane H. Hsiao Ph.D., MBA., 67
    Vice Chairman and Chief Technical Officer
    N/AN/A
    Mr. Steven D. Rubin J.D., 54
    Exec. VP of Admin. and Director
    465.00K0.00
    Mr. Juan F. Rodriguez , 47
    Consultant
    285.00K0.00
    Mr. Adam Logal , 35
    Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders